Dyne Therapeutics (NASDAQ:DYN) Hits New 52-Week Low – Here’s What Happened

Dyne Therapeutics, Inc. (NASDAQ:DYN)’s share price reached a new 52-week low during mid-day trading on Wednesday . The company traded as low as $13.08 and last traded at $13.33, with a volume of 13398 shares traded. The stock had previously closed at $13.52.

Analyst Ratings Changes

Several research firms have recently weighed in on DYN. Guggenheim reiterated a “buy” rating on shares of Dyne Therapeutics in a research note on Friday, January 24th. JPMorgan Chase & Co. downgraded Dyne Therapeutics from an “overweight” rating to a “neutral” rating and reduced their target price for the company from $43.00 to $35.00 in a research note on Thursday, October 24th. Baird R W upgraded Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Royal Bank of Canada restated an “outperform” rating and set a $45.00 price objective on shares of Dyne Therapeutics in a report on Tuesday, January 14th. Finally, Robert W. Baird began coverage on shares of Dyne Therapeutics in a research report on Friday, December 13th. They issued an “outperform” rating and a $46.00 price target for the company. One investment analyst has rated the stock with a sell rating, one has given a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Dyne Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $49.91.

Dyne Therapeutics Price Performance

The firm’s fifty day moving average is $19.76 and its two-hundred day moving average is $29.93. The firm has a market capitalization of $1.43 billion, a PE ratio of -3.95 and a beta of 1.11.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.96) EPS for the quarter, missing analysts’ consensus estimates of ($0.71) by ($0.25). As a group, equities research analysts predict that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity

In related news, insider Oxana Beskrovnaya sold 2,334 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $28.12, for a total value of $65,632.08. Following the transaction, the insider now owns 201,685 shares in the company, valued at approximately $5,671,382.20. This represents a 1.14 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Carlo Incerti sold 16,500 shares of the firm’s stock in a transaction on Monday, November 18th. The stock was sold at an average price of $28.73, for a total value of $474,045.00. The disclosure for this sale can be found here. Insiders sold a total of 20,289 shares of company stock valued at $580,592 in the last ninety days. 20.77% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. Quantbot Technologies LP bought a new stake in Dyne Therapeutics during the 3rd quarter valued at $34,000. Point72 DIFC Ltd bought a new stake in shares of Dyne Therapeutics during the 3rd quarter valued at $36,000. US Bancorp DE lifted its holdings in Dyne Therapeutics by 776.9% during the 3rd quarter. US Bancorp DE now owns 1,368 shares of the company’s stock worth $49,000 after purchasing an additional 1,212 shares in the last quarter. Values First Advisors Inc. bought a new position in Dyne Therapeutics in the 3rd quarter worth about $62,000. Finally, KBC Group NV grew its holdings in Dyne Therapeutics by 45.3% during the 4th quarter. KBC Group NV now owns 3,135 shares of the company’s stock valued at $74,000 after buying an additional 978 shares in the last quarter. Hedge funds and other institutional investors own 96.68% of the company’s stock.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.